Аннотация
Цель работы — изучение показателей цитокинового и свободно-радикального статуса пациентов, перенесших новую коро-
навирусную инфекцию через 8 и 12 недель от начала острого периода, выявление возможных предикторов развития пост-
ковидного синдрома.
Материал и методы. Под наблюдением находились 198 реконвалесцентов госпиталя особо опасных инфекций № 1 г. Нальчи-
ка. Больные перенесли острый период новой коронавирусной инфекции в средней и тяжелой формах. У пациентов определяли
сывороточные уровни ИЛ-1β, ИЛ-6, индекс ИМЦ (церулоплазмин/малоновый диальдегид). Оценивали изучаемые показатели в
качестве прогностических критериев развития постковидного синдрома путем вычисления отношения шансов.
Заключение. Предикторами развития постковидного синдрома может являться отсутствие нормализации иммунологиче-
ских показателей у больных с НКИ при выписке из госпиталя и через 8 недель от начала заболевания, таких как сывороточ-
ный уровень провоспалительных цитокинов ИЛ-6, ИЛ-8 и индекс ИЦМ (церулоплазмин/малоновый диальдегид).
Annotation
The aim of the work was to study the cytokine and free radical status indicators of patients who underwent a new coronavirus infection
after 8 and 12 weeks from the beginning of the acute period, as well as to identify possible immunological indicators as predictors
of the development of postcovid syndrome.
Material and methods. 198 convalescents of the hospital of especially dangerous infections No. 1 in Nalchik were under observation.
The patients underwent an acute period of SARS-CoV-2 infection in moderate and severe forms. Levels of serum IL-1β, IL-6, and the
BMI index (ceruloplasmin/malondialdehyde) were determined in convalescents. The studied indicators were evaluated as prognostic
criteria for the development of post-ovoid syndrome by calculating the odds ratio.
Conclusion. Predictors of the development of postcovoid syndrome may be the lack of normalization of immunological parameters of
patients with NKI during discharge from the hospital and 8 weeks from the onset of the disease, such as serum levels of proinflammatory
cytokines IL-6, IL-8 and the ICM index (ceruloplasmin/malondialdehyde).
Key words: COVID-19; postcovid syndrome; immunological indicators; predictors
Список литературы
Л И Т Е РАТ У РА ( П П . 1 — 1 2 , 1 4 , 1 5 , 1 7 , 1 8 , 2 0 —
3 2 С М . R E F E R E N C E S )
13. Скворцов В.В., Тумаренко А.В., Скворцова Е.М. , Штонда Д.А.
Постковидный синдром в практике терапевта. Врач. 2022; 4: 9-28.
DOI: 10.29296/25877305-2022-04-03.
16. Асфандиярова Н.С. Постковидный синдром. Клиническая меди-
цина. 2021; 99(7-8): 429-35. DOI: 10.30629/0023-2149-2021-99-7-
8-429-435.
19. Перетечикова А.В., Воскресенская О.Н. Клинические проявления
и вероятные предикторы формирования постковидного синдрома
в неврологической практике. Медицинский Совет. 2023;21: 168-
73. DOI: 10.21518/ms2023-427.
R E F E R E NC E S
1. Santos M., Dorna M., Franco E., Geronutti J., Brizola L., Ishimoto L.
et al. Clinical and physiological variables in patients with post-COVID-
19 condition and persistent fatigue. J. Clin. Med. 2024; 13(13):
3876. DOI: 10.3390/jcm13133876. PMID: 38999441; PMCID:
PMC11242482.
2. Chen K.K., Tsung-Ning Huang D., Huang L.M. SARS-CoV-2 variants
— еvolution, spike protein, and vaccines. Biomed. J. 2022; 45(4): 573-9.
DOI: 10.1016/j.bj.2022.04.006.
3. Chavda V.P., Patel A.B., Vaghasiya D.D. SARS-COV-2 variants and
vulnerability at the global level. J. Med. Virol. 2022; 94(7): 2986-3005.
DOI: 10.1002/jmv.27717.
4. Sinha K., Gutacker N., Gu Y., Haagsma J., Kumar K., Aghdaee M. Protocol
for a longitudinal study examining the trajectory of COVID-19,
post-COVID, multidimensional disadvantage and health-related
quality of life in India: the IndiQol Project. BMJ Open. 2024; 14(7):
e080985. DOI: 10.1136/bmjopen-2023-080985.
5. Varisco B., Bai F., De Benedittis S., Tavelli A., Cozzi-Lepri A., Sala
M. et al. EuCARE-POSTCOVID Study: a multicentre cohort study
on long-term post-COVID-19 manifestations. BMC Infect. Dis. 2023;
23(1): 684. DOI: 10.1186/s12879-023-08595-0.
6. Alkodaymi M.S., Omrani O.A., Fawzy N.A., Shaar B.A., Almamlouk
R., Riaz M. et al. Prevalence of post-acute COVID-19 syndrome symptoms
at different follow-up periods: a systematic review and meta-analysis.
Clin. Microbiol. Infect. 2022; 28(5): 657-66. DOI: 10.1016/j.
cmi.2022.01.014.
7. Jasem ZA, Manee F, Alqattan DM, Smith TM. Impact of post-acute
sequelae of COVID-19 on lives of patients post-intensive care unit discharge:
A cross-sectional study. Med. Princ. Pract. 2024; 33(5): 452-
61. DOI: 10.1159/000539781.
8. André S., Bruyneel A.V., Chirumberro A., Roman A., Claus M., Alard
S. et al. Health-related quality of life improves in parallel with FEV1
and 6-minute walking distance test at between 3 and 12 months in
critical COVID-19 survivors. Am. J. Med. Open. 2023; Aug 23; 10:
100055. DOI: 10.1016/j.ajmo.2023.100055.
9. Patterson B.K., Francisco E.B., Yogendra R., Long E., Pise A. et al. Persistence
of SARS COV-2 S1 protein in CD16+ monocytes in post-acute
sequelae of COVID-19 (PASC) up to 15 months post-infection. Front.
Immunol. 2022; 12: 746021. DOI: 10.3389/fimmu.2021.746021.
10. COVID-19 rapid guideline: managing the long-term effects of
COVID-19 NICE guideline [NG188] Published date: 18 December
2020; https://www.nice.org.uk/guidance/ng188.
11. Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re’em Y. et
al. Characterizing long COVID in an international cohort: 7 months
of symptoms and their impact. EClinicalMedicine. 2021; 38: 101019.
DOI: 10.1016/j.eclinm.2021.101019.
12. Klitzman R.L. Needs to prepare for «Post-COVID-19 syndrome». Am.
J. Bioeth. 2020; 20(11): 4-6. DOI: 10.1 080/15265161.2020.1820755.
13. Skvortsov V.V., Tumarenko A.V., Skvortsova E.M., Shtonda D.A.
Postcovoid syndrome in the practice of a therapist. Vrach. 2022; 4:
9-28. DOI: 10.29296/25877305-2022-04-03. (in Russian)
14. Tenforde M.W., Kim S.S., Lindsell C.J., Billig R. E., Shapiro N.I., Files
D.C. et al. Symptom duration and risk factors for delayed return to usual
health among outpatients with COVID-19 in a multistate health care
systems Network — United States, March-June 2020. MMWR Morb.
Mortal. Wkly. Rep. 2020; 69(30): 993-8. DOI: 10.15585/mmwr.
mm6930e1.
15. Petersen M.S., Kristiansen M.F., Hanusson K.D., Danielsen M.E., Á
Steig B., Gaini S. et al. Long COVID in the Faroe Islands: a longitudinal
study among nonhospitalized patients. Clin. Infect. Dis. 2021;
73(11): e4058-e4063. DOI: 10.1093/cid/ciaa1792.
16. Asfandiyarova N.S. Postcovoid syndrome. Klinicheskaya meditsina.
2021; 99(7-8): 429-35. DOI: 10.30629/0023-2149-2021-99-7-8-429-
435. (in Russian)
17. Augustin M., Schommers P., Stecher M., Dewald F., Gieselmann L.,
Gruell H. et al. Post-COVID syndrome in non-hospitalised patients
with COVID-19: a longitudinal prospective cohort study. Lancet Reg.
Health Eur. 2021; 6: 100122. DOI: 10.1016/j.lanepe.2021.100122.
18. Sudre C.H., Murray B., Varsavsky T., Graham M.S., BowyeK R.C.,
Pujol J.C. et al. Attributes and predictors of long COVID. Nat. Med.
2021; 27: 626-31. DOI: 10.1038/s41591-021-01292-y.
19. Peretechikova A.V, Voskresenskaya O.N. Clinical manifestations
and probable predictors of the formation of postcovoid syndrome in
neurological practice. Meditsinskiy Sovet. 2023; 21: 168-73. DOI:
10.21518/ms2023-427. (in Russian)
20. Coronel P.M.V., Pereira I.C., Basilio D.C.L.S., Espinoça I.T., de Souza
K.F.S., Ota R.S.N. et al. Biomarkers of oxidative stress and inflammation
in subjects with COVID-19: Characterization and prognosis of
the disease. Microb. Pathog. 2023; 184: 106339. DOI: 10.1016/j.
micpath.2023.106339.
21. Arnaud P., Gianazza E., Miribel L. Ceruloplasmin. Methods Enzymol.
1988; 163: 441-52. DOI: 10.1016/0076-6879(88)63042-4.
22. Cavaillon J.M., Munoz C., Fitting C., Misset B., Carlet J. Circulating
cytokines: the tip of the iceberg? Circ. Shock. 1992; 38(2): 145-52.
PMID: 1423923.
23. Adam D. COVID’s true death toll: much higher than official records.
Nature. 2022; 603(7902): 562. DOI: 10.1038/d41586-022-00708-0.
PMID: 35277684.
24. Rabol Andersen L., Hindsberger B., Bastrup Israelsen S., Pedersen L.,
Bela Szecsi P., Benfield T. Higher levels of IL-1ra, IL-6, IL-8, MCP-1,
MIP-3α, MIP-3β, and fractalkine are associated with 90-day mortality in
132 non-immunomodulated hospitalized patients with COVID-19. PLoS
One. 2024; 19(7): e0306854. DOI: 10.1371/journal.pone.0306854.
25. Smail S.W., Babaei E., Amin K., Abdulahad W.H. Serum IL-23, IL-10,
and TNF-α predict in-hospital mortality in COVID-19 patients. Front.
Immunol. 2023; 14: 1145840. DOI: 10.3389/fimmu.2023.1145840.
26. Krueger J.G., Eyerich K., Kuchroo V.K., Ritchlin C.T., Abreu M.T., Elloso
M.M. et al. IL-23 past, present, and future: a roadmap to advancing
IL-23 science and therapy. Front. Immunol. 2024; 15: 1331217.
DOI: 10.3389/fimmu.2024.1331217.
27. Moulton C.D., Malys M., Hopkins C.W.P., Rokakis A.S., Young A.H.,
Powell N. Activation of the interleukin-23/Th17 axis in major depression:
a systematic review and meta-analysis. Eur. Arch. Psychiatry
Clin. Neurosci. 2024; Jul 16. DOI: 10.1007/s00406-024-01864-2.
28. Kharaeva Z., Shokarova A., Shomakhova Z., Ibragimova G., Trakhtman
P., Trakhtman I. et al. Fermented Carica papaya and Morinda
citrifolia as perspective food supplements for the treatment of post-
COVID symptoms: randomized placebo-controlled clinical laboratory
study. Nutrients. 2022; 14(11): 2203. DOI: 10.3390/nu14112203.
29. Kiełbowski K., Herian M., Pawlik A. How to restore oxidative balance
that was disrupted by SARS-CoV-2 infection. Int. J. Mol. Sci. 2022;
23(12): 6377. DOI: 10.3390/ijms23126377.
30. Kadam S.B., Sukhramani G.S., Bishnoi P., Pable A.A., Barvkar V.T.
SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights.
J. Basic. Microbiol. 2021; 61(3): 180-202. DOI: 10.1002/
jobm.202000537.
31. Zhu J., Bouzid R., Travert B., Géri G., Cohen Y., Picod A. et al. Combined
coagulation and inflammation markers as predictors of venous
thrombo-embolism and death in COVID-19. Front. Med. (Lausanne).
2024; 11: 1399335. DOI: 10.3389/fmed.2024.1399335.
32. Satış H., Özger H.S., Aysert Yıldız P., Hızel K., Gulbahar Ö., Erbaş G.
et al. Prognostic value of interleukin-18 and its association with other
inflammatory markers and disease severity in COVID-19. Cytokine.
2021; 137: 155302. DOI: 10.1016/j.cyto.2020.155302.